Some of the names on the move ahead of the open.» Read More
Jan 5- Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies. Gilead's shares rose 1 percent to $99 in premarket trading. The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016..
Jan 5- Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies. The drug, tenofovir alafenamide, or TAF, also showed improved renal and bone safety compared with Viread, Gilead said on Tuesday. Gilead plans to submit regulatory applications for TAF in the United...
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
Stock picking will once again rule in 2016, according to strategists on Wall Street. Here are 10 names to consider.
“Mad Money” host Jim Cramer is telling investors which stock is headed higher for the long-term.
Jim Cramer prepares investors for the biotech group to come roaring back in 2016, and shares his top picks.
The latest drug-price increases are just the tip of the iceberg, explains former Medtronic CEO Bill George.
Dec 18- As Turing Pharmaceuticals Chief Executive Officer Martin Shkreli contends with charges of securities fraud, major U.S. pharmacies are moving to assure patients of continued access to the company's key drug, Daraprim. CVS Health Corp, the No. 2 U.S. drug benefit manager, told Reuters on Thursday it can provide an alternative to Daraprim that is compounded...
Dec 17- The U.S. Food and Drug Administration has postponed by three months its decision on Intercept Pharmaceuticals Inc's marketing application for its lead drug, to treat a kind of liver disease. Intercept said the FDA would now announce its decision on May 29 as it required more time to analyze additional clinical data submitted by the company.
Drug pricing has become a contentious issue among drugmakers and lawmakers in the United States, with companies like Valeant Pharmaceuticals and Turing Pharmaceuticals facing a backlash for sharply hiking prices of older drugs they have bought cheaply. Pharnext thinks it can sell its promising drug- a combination of three already-approved drugs- for...
*Yellen gives Congress upbeat view on march towards liftoff. Dec 3- U.S. stocks were sharply lower on Thursday as European Central Bank's minimal rate cut and extended stimulus failed to impress investors, and Federal Reserve Chair Janet Yellen's comments hardened expectations of an interest rate hike this month. European shares suffered their biggest fall...
Shares of medtech companies such as Edwards Lifesciences, Boston Scientific and Becton Dickinson have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, over the past two months since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug "price gouging." He said he likes...
Roughly two-thirds of the top 50 innovative companies are not squarely in technology, according to a ranking by The Boston Consulting Group.
The national conversation on drug prices is getting louder, and patients increasingly want a voice in that discussion.
This dividend health rating system predicts which dividends are likely to rise or fall. Which stocks made the cut?
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
Here's how the Fed could play Grinch and wreck the Santa Claus rally, says Ron Insana.
Jim Cramer gives his opinion on various caller favorite stocks, including this hated biotech play.
Nov 17- The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The United States and New Zealand are the only two countries that allow direct-to-consumer advertising...